Epidemiological and clinical features of pregnant women with HIV: a 21-year perspective from a highly specialized regional center in southern Italy.

Abstract:

PURPOSE:To analyze the changes over two decades in HIV-infected pregnant women followed at a highly specialized regional center for antenatal care in southern Italy. METHOD:Since 1985, all HIV-infected pregnant women attending our center have been monitored using progressively updated protocols. RESULTS:By December 2006, 230 deliveries in 159 women had been monitored. Deliveries in HIV-infected women increased from 0.16% (4/2,499) of all deliveries in 1985 to 0.73% (15/2,042) in 2006. The sociodemographic profile of the women changed greatly over the study period, and there was a shift from injecting drug use to heterosexual contact as the main transmission route and an increased proportion of foreign women. Subsequent to improvements in clinical care, the proportion of infected pregnant women receiving antiretroviral treatment increased from 27% (17/63) before 1996 to 81% (63/78) in 2006, with a corresponding decrease in the mother-to-child transmission rate from 36% (16/44) to 0.6% (1/157). CONCLUSION:The increasing number of HIV-infected pregnant women can be attributed to nonselective antenatal HIV screening, the spread of HIV infection through heterosexual contacts, and the desire of HIV-infected women to have children. In this context, highly specialized reference centers can play an important role in providing HIV-infected pregnant women with optimal care and in reducing mother-to-child transmission rates to very low levels.

journal_name

HIV Clin Trials

journal_title

HIV clinical trials

authors

Martinelli P,Agangi A,Sansone M,Maruotti GM,Buffolano W,Paladini D,Pizzuti R,Floridia M

doi

10.1310/hct0901-36

subject

Has Abstract

pub_date

2008-01-01 00:00:00

pages

36-42

issue

1

eissn

1528-4336

issn

1945-5771

pii

Q43P715QT151823K

journal_volume

9

pub_type

杂志文章
  • Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

    abstract:OBJECTIVES:Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in pooled data from 2 phase 3 studies. METHODS:ECHO and THRIVE are double...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,随机对照试验

    doi:10.1310/hct1403-81

    authors: Nelson MR,Elion RA,Cohen CJ,Mills A,Hodder SL,Segal-Maurer S,Bloch M,Garner W,Guyer B,Williams S,Chuck S,Vanveggel S,Deckx H,Stevens M

    更新日期:2013-05-01 00:00:00

  • A pilot, prospective, open-label simplification study to evaluate the safety, efficacy, and pharmacokinetics of once-daily lopinavir-ritonavir monotherapy in HIV-HCV coinfected patients: the MONOCO study.

    abstract:BACKGROUND:A safe, effective, easy-to-dose antiretroviral therapy that minimizes hepatic complication risk is essential in optimizing HIV-HCV treatment. Nucleoside-sparing boosted protease inhibitor monotherapy may achieve this goal. METHODS:A prospective, open-label pilot simplification study of once-daily lopinavir/...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/hct1304-179

    authors: Cooper C,la Porte C,Tossonian H,Sampalis J,Ackad N,Conway B

    更新日期:2012-07-01 00:00:00

  • Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes.

    abstract:BACKGROUND:Multiple resistance to nucleoside analogs mediated by the Q151M complex and/or codon 67-69 inserts/deletions represents a growing problem among HIV-infected persons, most of whom have been exposed to sequential therapies for long periods of time. PATIENTS AND METHOD:All plasma samples collected from HIV-inf...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/X618-KWKJ-WCTQ-LQ2L

    authors: Gallego O,d Mendoza C,Labarga P,Altisent C,González J,García-Alcalde I,Valer L,Valencia E,Soriano V

    更新日期:2003-11-01 00:00:00

  • Exercise training reduces oxidative stress in people living with HIV/AIDS: a pilot study.

    abstract:BACKGROUND:Exercise training has been shown to be an effective strategy to balance oxidative stress status; however, this is underexplored in people living with HIV/AIDS (PLWHA). OBJECTIVE:To evaluate the effects of exercise training on oxidative stress in PLWHA receiving antiretroviral therapy. METHODS:Patients perf...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/15284336.2018.1481247

    authors: Deresz LF,Schöler CM,de Bittencourt PIHJ,Karsten M,Ikeda MLR,Sonza A,Dal Lago P

    更新日期:2018-08-01 00:00:00

  • Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

    abstract:BACKGROUND:Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) available in clinical practice. Three independent pathways have been described to confer resistance to RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions with an uncerta...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,多中心研究

    doi:10.1310/hct1401-10

    authors: Gutiérrez C,Hernández-Novoa B,Pérez-Elías MJ,Moreno AM,Holguín A,Dronda F,Casado JL,Moreno S

    更新日期:2013-01-01 00:00:00

  • Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening.

    abstract:BACKGROUND:In the HIV Prevention Trials Network (HPTN) 061 study, 8 (2.3%) of 348 HIV-infected participants identified as HIV uninfected at study enrollment using a single HIV rapid test for screening were found to be HIV infected after additional testing. OBJECTIVES:To evaluate the performance of different HIV assays...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/hct1502-62

    authors: Piwowar-Manning E,Fogel JM,Laeyendecker O,Wolf S,Cummings V,Marzinke MA,Clarke W,Breaud A,Wendel S,Wang L,Swanson P,Hackett J Jr,Mannheimer S,Del Rio C,Kuo I,Harawa NT,Koblin BA,Moore R,Blankson JN,Eshleman SH

    更新日期:2014-03-01 00:00:00

  • Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.

    abstract:PURPOSE:Recent trials suggest serious toxicity in HIV-associated non-Hodgkin's lymphoma (NHL) with rituximab (R) and chemotherapy (CT), offsetting the benefit of rituximab. METHOD:We retrospectively reviewed experience with CHOP-R vs. CT in 40 patients with HIV-associated diffuse large B-cell lymphoma (DLBCL) diagnose...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0803-132

    authors: Ezzat H,Filipenko D,Vickars L,Galbraith P,Li C,Murphy K,Montaner JS,Harris M,Hogg RS,Vercauteren S,Leger CS,Zypchen L,Leitch HA

    更新日期:2007-05-01 00:00:00

  • Simplification and first validation of a short battery of patient questionnaires for clinical management of HIV-infected patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire.

    abstract:PURPOSE:Questionnaires assessing patient-reported outcomes in HIV are either too long or not HIV-specific. Our aim was to develop and validate a simplified HIV patient questionnaire. METHOD:607 HIV patients treated with a combination of antiretroviral (ARV) drugs were enrolled in an observational, longitudinal study. ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1004-215

    authors: Spire B,Arnould B,Barbier F,Durant J,Gilquin J,Landman R,Carret S,Saussier C,El Kebir S,Cohen-Codar I

    更新日期:2009-07-01 00:00:00

  • Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.

    abstract:PURPOSE:Treatment options for HIV-associated lipodystrophy syndrome (HALS) remain limited. The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS. METHOD:Sixty-four subjects received daily ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1310/hct0904-254

    authors: Macallan DC,Baldwin C,Mandalia S,Pandol-Kaljevic V,Higgins N,Grundy A,Moyle GJ

    更新日期:2008-07-01 00:00:00

  • HIV pharmacology: barriers to the eradication of HIV from the CNS.

    abstract::Total eradication of HIV-1 is not yet achievable, in part because reservoirs of latent HIV-1 can develop within lymphoid tissue, the testes, and the central nervous system (CNS). The presence of HIV-1 in the CNS is clinically significant because of its association with the development of HIV dementia, which occurs in ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/AW2H-TP5C-NP43-K6BY

    authors: McGee B,Smith N,Aweeka F

    更新日期:2006-05-01 00:00:00

  • Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.

    abstract:PURPOSE:To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted. METHOD:Participants received 250-mg self-emulsifying dru...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1310/RRX7-49ME-27V7-MWWV

    authors: MacGregor TR,Sabo JP,Norris SH,Johnson P,Galitz L,McCallister S

    更新日期:2004-11-01 00:00:00

  • Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes.

    abstract::Naturally occurring polymorphisms at positions involved in resistance to antiretroviral agents are frequently seen in HIV-1 non-B subtypes. Although they do not seem to affect significantly the susceptibility to antiretroviral drugs in vitro, they may facilitate the selection of different pathways and/or a more rapid ...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/7bwp-0x7f-nxna-qrnp

    authors: Holguín A,Soriano V

    更新日期:2002-09-01 00:00:00

  • Database-supported teleconferencing: an additional clinical mentoring tool to assist a multinational company HIV/AIDS treatment program in Africa.

    abstract:BACKGROUND:The lack of human resources for health is presently recognized as a major factor limiting scale-up of antiretroviral treatment (ART) programs in resourcelimited settings. The mobilization of public and private partners, the decentralization of care, and the training of non-HIV specialist nurses and general p...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0705-255

    authors: Clevenbergh P,Van der Borght SF,van Cranenburgh K,Janssens V,Kitenge Lubangi C,Gahimbaza L,Lange JM,Rinke de Wit TF,Rijckborst H

    更新日期:2006-09-01 00:00:00

  • Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study.

    abstract:BACKGROUND:Endothelial progenitor cells (EPCs) are bone marrow-derived cells that contribute to vascular repair. EPCs may be reduced in HIV-infected (HIV+) persons, contributing to cardiovascular disease (CVD). Telmisartan is an angiotensin receptor blocker that increases EPCs in HIV-uninfected adults. OBJECTIVE:To as...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1080/15284336.2016.1234222

    authors: Lake JE,Seang S,Kelesidis T,Currier JS,Yang OO

    更新日期:2016-11-01 00:00:00

  • Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?

    abstract:PURPOSE:Proven clinical efficacy of protease-sparing regimens (PSR) has been shown. Concerns exist about broad applicability of these regimens in advanced naïve patients. Recent reports have associated a rise in liver enzymes with nevi rapine; however, no data exist with efavirenz. METHOD:17 consecutive antiretroviral...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/2V0B-HDWC-AGWR-H56M

    authors: Corales RB,Shrestha NK,Taege AJ,Isada CM,Rehm SJ,Schmitt SK,Gordon SM,Mawhorter SD

    更新日期:2001-01-01 00:00:00

  • Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

    abstract:PURPOSE:Selecting the optimal treatment regimen for antiviral-naive patients may be difficult, given the concern about the antiviral activity, the development of drug resistance, and the increase in drug costs. This study evaluates the costs and effectiveness of using lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV), b...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/WT81-MEM4-5C4L-CHPK

    authors: Simpson KN,Luo MP,Chumney E,Sun E,Brun S,Ashraf T

    更新日期:2004-09-01 00:00:00

  • A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

    abstract:OBJECTIVE:To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue. METHODS:Individual patient data from placebo-controlled, randomized trials of rosiglitazone (n = 5) or pioglitazone (n = 1) were combined. Gen...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,meta分析

    doi:10.1310/hct1101-39

    authors: Raboud JM,Diong C,Carr A,Grinspoon S,Mulligan K,Sutinen J,Rozenbaum W,Cavalcanti RB,Wand H,Costagliola D,Walmsley S,Glitazone and Lipoatrophy Meta-Analysis Working Group.

    更新日期:2010-01-01 00:00:00

  • Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.

    abstract:PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/HAG3-8YA5-UDQC-36NX

    authors: Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

    更新日期:2005-03-01 00:00:00

  • Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.

    abstract:OBJECTIVES:Despite substantial improvements in HIV outcomes with combination antiretroviral therapy (cART), morbidity and mortality remain above population norms. The gut mucosal immune system is not completely restored by cART, and the resultant microbial translocation may contribute to chronic inflammation, inadequat...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1080/15284336.2016.1184827

    authors: Kim CJ,Walmsley SL,Raboud JM,Kovacs C,Coburn B,Rousseau R,Reinhard R,Rosenes R,Kaul R

    更新日期:2016-07-01 00:00:00

  • Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

    abstract:OBJECTIVE:To evaluate the safety profile and efficacy of salvage regimens containing amprenavir (APV) 600 mg twice daily and ritonavir (RTV) 200 mg twice daily. DESIGN:Prospective, single-center study. METHOD:The patient database of the department of infectious diseases was screened for patients who had failed at lea...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/RFT5-7N0M-8C5G-0TL2

    authors: Arvieux C,Tattevin P,Souala FM,Jaccard P,Ruffault A,Bentué-Ferrer D,Tribut O,Chapplain JM,Dupont M,Bouvier C,Michelet C

    更新日期:2002-03-01 00:00:00

  • Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain.

    abstract:OBJECTIVE:To determine the prevalence of CCR5-tropic HIV-1 among treatment-experienced patients in Spain. DESIGN:Epidemiologic, cross-sectional, and non-interventional study between January and June 2008 in HIV-1-infected patients in Spain. METHODS:A total of 485 treatment-experienced patients from across Spainand wi...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1006-394

    authors: Moreno,Clotet,Sarría,Ortega,Leal,Rodriguez-Arrondo,Sánchez-de la Rosa,Allegro Study Group.

    更新日期:2009-11-01 00:00:00

  • Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.

    abstract:BACKGROUND:The success of longitudinal trials depends greatly on using effective strategies to retain participants and ensure internal validity, maintain sufficient statistical power, and provide for the generalizability of study results. OBJECTIVE:This paper describes the challenges and specific strategies used to re...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/15284336.2018.1513711

    authors: Wynne J,Muwawu R,Mubiru MC,Kamira B,Kemigisha D,Nakyanzi T,Kabwigu S,Nakabiito C,Kiweewa Matovu F

    更新日期:2018-10-01 00:00:00

  • Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.

    abstract:BACKGROUND:Simple antiretroviral drug combinations might provide a comparable benefit to standard triple regimens in patients with mild HIV disease, because poor adherence and toxicities often compromise the sustained benefit of the latest triple regimens, especially when protease inhibitors are used. Bad adherence is ...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1310/FAJF-7A8G-QAR4-Q0X5

    authors: de Mendoza C,Ramos JT,Ciria L,Fortuny C,García FJ,de José MI,Asensi F,Soriano V

    更新日期:2002-01-01 00:00:00

  • A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy.

    abstract:PURPOSE:To prospectively determine incidence, prevalence, and extent of lipodystrophy (LD) and associated metabolic changes. METHOD:This was a prospective cohort study. Body habitus changes were determined by anthropometrics, photography, and regional dual-energy X-ray absorptiometry (DXA) scan. Metabolic parameters i...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct0905-314

    authors: Walmsley S,Cheung AM,Fantus G,Gough K,Smaill F,Azad,Diong C,Raboud J

    更新日期:2008-09-01 00:00:00

  • Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.

    abstract:UNLABELLED:Patients with prior virologic failure (VF) are at an increased risk of subsequent failure, emergence of resistance, and death. This analysis identifies outcomes and correlates of VF in a high-risk population. METHODS:A5251 was designed to evaluate an enhanced adherence counseling intervention delivered by n...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/15284336.2016.1189754

    authors: Robbins GK,Cohn SE,Harrison LJ,Smeaton L,Moran L,Rusin D,Dehlinger M,Flynn T,Lammert S,Wu AW,Safren SA,Reynolds NR

    更新日期:2016-07-01 00:00:00

  • Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls.

    abstract:BACKGROUND:Perinatally acquired HIV-infected (PaHIV) young adults undergo neurodevelopment in the presence of HIV infection and antiretroviral therapy, which may lead to neurocognitive (NC) impairment. Knowledge of NC function in this group is sparse and control data lacking. We compared cerebral function in young adul...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1179/1528433614Z.0000000003

    authors: Ashby J,Foster C,Garvey L,Wan T,Allsop J,Paramesparan Y,Taylor-Robinson SD,Fidler S,Winston A

    更新日期:2015-03-01 00:00:00

  • Update on HIV lipodystrophy.

    abstract::When prescribed appropriately and taken adherently, antiretroviral therapy can consistently and durably suppress HIV replication, potentially translating into years of near normal health for HIV-infected persons. However, presently available antiretrovirals are associated with a cluster of physical and metabolic sympt...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,评审

    doi:10.1310/XP75-7VJ5-HML2-YF1W

    authors: Kravcik S

    更新日期:2004-05-01 00:00:00

  • Determinants of participation in HIV clinical trials: the importance of patients' trust in their provider.

    abstract:PURPOSE:To investigate the factors that contribute to willingness to participate in HIV clinical trials and to determine the impact of a brief intervention on willingness to participate. METHODS:115 consecutive outpatients receiving HIV primary care participated in this prospective study. Each patient completed a ques...

    journal_title:HIV clinical trials

    pub_type: 杂志文章

    doi:10.1310/hct1002-104

    authors: Volkmann ER,Claiborne D,Currier JS

    更新日期:2009-03-01 00:00:00

  • The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.

    abstract:PURPOSE:To assess the effect of changing antiretroviral therapy in patients initially treated with saquinavir hard gel capsule (hgc). METHOD:A retrospective cohort study comparing the virological and immunological responses in antiretroviral-naïve patients initially treated with a regimen of saquinavir-hgc, zidovudine...

    journal_title:HIV clinical trials

    pub_type: 临床试验,杂志文章

    doi:10.1310/KED4-8TW3-4ARG-HFC5

    authors: Jensen-Fangel S,Kirk O,Blaxhult A,Gerstoft J,Pedersen C,Black FT,Lundgren JD,Obel N

    更新日期:2001-03-01 00:00:00

  • Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.

    abstract:OBJECTIVE:To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naïve subjects through 144 weeks. METHOD:This was a randomized, double-blind,...

    journal_title:HIV clinical trials

    pub_type: 杂志文章,随机对照试验

    doi:10.1310/hct1505-218

    authors: Kulkarni R,Abram ME,McColl DJ,Barnes T,Fordyce MW,Szwarcberg J,Cheng AK,Miller MD,White KL

    更新日期:2014-09-01 00:00:00